Updated and additional risk factors as of August 14, 2017

Attention is drawn to the risk factors described in chapter 4 of the Document de Référence for 2016. The following risk factors supplement and should be read in conjunction with those risk factors described in the Document de Référence.

The timing of potential approval for latanoprostene bunod remains unclear, the approval may face significant delays or latanoprostene bunod may never obtain approval. Any delay in or failure to obtain approval could negatively affect Nicox's business, financial condition, prospects and stock price.

On August 8, 2017, Nicox announced that it had been informed by its partner Bausch + Lomb (a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.) of the receipt of a Complete Response Letter ("CRL") from the United States Food and Drug Administration (the "FDA") concerning latanoprostene bunod. This CRL follows a July 22, 2016 CRL received by Bausch + Lomb from the FDA concerning latanoprostene bunod. In each case, the concerns raised by the FDA pertain to a Current Good Manufacturing Practice (CGMP) inspection at Bausch + Lomb's manufacturing facility in Tampa, Florida. In each case, the FDA's letter did not identify any efficacy or safety concerns with respect to the new drug application or additional clinical trials needed for the approval of the new drug application for latanoprostene bunod.

Nicox does not currently have any additional information related to the specific details of the FDA's concerns following receipt of the CRL announced on August 8, 2017, nor does it have an estimate of the amount of time it will take for the issue to be resolved. Valeant has announced its intention to meet with the FDA as soon as possible to work on a resolution and address the FDA's concerns, but no assurance can be provided that the identified deficiencies can be resolved promptly or at all. Any delay in the approval of latanoprostene bunod could be negatively perceived by the market and negatively impact Nicox's business, financial condition and prospects, and there is no assurance that latanoprostene bunod will be approved for commercialization by the FDA or other regulators.

The development of NCX 4251 and NCX 470 could be delayed or fail

NCX 4251 is a pharmaceutical product based on a repurposed molecule administered in a new formulation by a new route, while NCX 470 is a pharmaceutical product based on a new chemical entity (NCE).

While a product based on an NCE is much more likely to encounter an unpredictable and, therefore, unexpected adverse effect of the NCE which would require additional studies (and the associated time and cost) to resolve (if it can be resolved), neither of NCX 4251 nor NCX 470 has entered phase 2 of clinical development yet, and there is a risk that additional studies prove necessary before the development of either of those products can be moved forward.

Drug discovery and development is inherently risky and unpredictable. Forecasts of timelines are variable by nature and subject to adjustments. While we currently anticipate to submit the IND for each of those products by the end of Q1 2018, which represents a delay from prior guidance, there is no guarantee that Nicox can submit an IND for either NCX 4251 or NCX 470 in the future.

Our product candidate development costs will increase if we experience delays in testing or approvals. We may accordingly be required to obtain additional funds in order to complete clinical trials and prepare for possible commercialization of our product candidates, or we may decide to interrupt, further delay or reassess whether to pursue trials for NCX 4251 or NCX 470, which could have a material adverse effect on our business and result of operations.

There are associated risks to the commercial launch of ZERVIATE (AC-170)

To date, Nicox has no commercial infrastructure in the US. Nicox must consider a number of options for putting ZERVIATE on the market, including concluding one or several sales, license or distributions agreements with third parties or creating a new American commercial infrastructure to directly promote ZERVIATE.

In the absence of a Nicox commercial operation in the United States, we will need to find a partner for ZERVIATE before we will be able to commercialize the product. There is no guarantee that we will be able to find a partner. Even if we find a partner, we expect that the terms upon which we engage such a partner will require us to reduce the value of our assets on our balance sheet on the assumption that the estimated future value of the revenue from such partnership is considered to be lower than we initially expected. The value of any such impairment would be determined in connection with IFRS accounting principles and agreed with our auditors, with whom the Company is currently engaged in related discussions. Further, there is no assurance that the Company will be able to conclude an agreement on favourable terms which will provide Nicox with the expected return, which could have a material adverse effect on our financial condition and results of operations.